Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

AstraZeneca - Key questions on PARP inhibitors in ovarian cancer: Experts evaluate the latest evidence

How can we proactively manage PARP inhibitor-related adverse events to improve quality of life for patients?

Date

25 Jun 2021

Session

AstraZeneca - Key questions on PARP inhibitors in ovarian cancer: Experts evaluate the latest evidence

Presenters

Frederik Marmé

Authors

F. Marmé

Author affiliations

  • UMM - Universitaetsklinikum Mannheim, Mannheim/DE
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings